All In Biotech

Drug Trial Radar · NCT06586242

Efficacy and Safety of Penpulimab Combined With Anlotinib and Chemotherapy

A Two Arm, Randomized, Prospective, Multicenter Study of Penpulimab Combined With Anlotinib Hydrochloride and Chemotherapy in the Perioperative Treatment of Locally Advanced Resectable Esophageal Cancer

Last checked: Nov 19, 2026Latest source record: Sep 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 194 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

194

Planned (sponsor's estimate)

Start

Apr 3, 2023

Primary completion

Apr 2025

Study completion Apr 2036

Sponsor

Lead sponsor
Xijing HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Sep 19, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Single (investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a two arm, randomized, prospective, multicenter study on the perioperative treatment of locally advanced resectable esophageal cancer with penpulimab combined with anlotinib hydrochloride and chemotherapy.

Conditions

  • Esophageal Cancer

Interventions

  • Penpulimab;Anlotinib;albumin paclitaxel;oxaliplatin;lobaplatinDrug

    200mg, intravenous infusion, 30-60 minutes per infusion, once every 3 weeks, Penpulimab:administered on the first day of each cycle Anlotinib:Body weight \<60kg, 8mg Po, body weight ≥ 60kg, 10mg Po, D 1-14, q3w

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. the Pathological complete response (PCR) rateTime frame: 2years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of the Air Force Medical University

    Xi'an, Shaan'xi, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.